Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?

Transfusion and Apheresis Science

Volumn 37, Issue 1, 2007, Pages 37-41

  Diehl, Volker ^a   Fuchs, Michael ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINBLASTINE SULFATE; VINCRISTINE; VINCRISTINE SULFATE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; NONHODGKIN LYMPHOMA; RADIATION DOSE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CLINICAL TRIALS AS TOPIC; CYCLOPHOSPHAMIDE; DACARBAZINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; HEART DISEASES; HODGKIN DISEASE; HUMANS; INFERTILITY; LUNG DISEASES; MECHLORETHAMINE; MULTICENTER STUDIES AS TOPIC; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; PREDNISONE; PROCARBAZINE; RISK; SURVIVAL RATE; VINBLASTINE; VINCRISTINE;

EID: 35348821878     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2007.04.004     Document Type: Article

References (14)

1. DeVita Jr. V.T., and Carbone P.P. Treatment of Hodgkin's disease. Med Ann Dist Columbia 36 (1967) 232-234 passim
2. Bonadonna G., Zucali R., Monfardini S., De Lena M., and Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36 (1975) 252-259
3. Jones S.E., Haut A., Weick J.K., Wilson H.E., Grozea P., Fabian C.J., et al. Comparison of adriamycin-containing chemotherapy (MOP-BAP) with MOPP-Bleomycin in the management of advanced Hodgkin's disease: a Southwest oncology group study. Cancer 51 (1983) 1339-1347
4. Viviani S., Bonadonna G., Santoro A., Bonfante V., Zanini M., Devizzi L., et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol 14 (1996) 1421-1430
5. Glick J.H., Young M.L., Harrington D., Schilsky R.L., Beck T., Neiman R., et al. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol 16 (1998) 19-26
6. Duggan D.B., Petroni G.R., Johnson J.L., Glick J.H., Fisher R.I., Connors J.M., et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 21 (2003) 607-614
7. Horning S.J., Hoppe R.T., Breslin S., Bartlett N.L., Brown B.W., and Rosenberg S.A. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 20 (2002) 630-637
8. Gobbi P.G., Levis A., Chisesi T., Broglia C., Vitolo U., Stelitano C., et al. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate - and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 23 (2005) 9198-9207
9. Radford J.A., Rohatiner A.Z., Ryder W.D., Deakin D.P., Barbui T., Lucie N.P., et al. J Clin Oncol 20 (2002) 2988-2994
10. Diehl V., Franklin J., Pfreundschuh M., Lathan B., Paulus U., Hasenclever D., et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348 (2003) 2386-2395
11. Hasenclever D., Loeffler M., and Diehl V. Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. German Hodgkin's lymphoma study group. Ann Oncol 7 Suppl. 4 (1996) 95-98
12. Sieber M., Bredenfeld H., Josting A., Reineke T., Rueffer U., Koch T., et al. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21 (2003) 1734-1739
13. Diehl V., Brillant C., Franklin J., Hermann R., Greil R., Engert A., et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9- and HD12- trials of the German Hodgkin Study Group (GHSG). Blood 104 (2004) 307a
14. Aleman B.M., Raemaekers J.M., Tirelli U., Bortolus R., van 't Veer M.B., Lybeert M.L., et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 348 (2003) 2396-2406